Dongsheng Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dongsheng Cao has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Dehui Che
Department of Plastic and Reconstructive The Second Affiliated Hospital of Anhui Medical University Hefei China
5 shared publicationsJuan Xie
Department of Plastic and Reconstructive, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
3 shared publicationsYan Liu
Department of Plastic and Reconstructive, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
3 shared publicationsYujiao Cai
Department of Plastic and Reconstructive, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
3 shared publicationsBangzhong Zhu
Department of Plastic and Reconstructive, The Second Affiliated Hospital of Anhui Medical University, Furong Road 678#, Shushan Dist., Hefei, 238000, People's Republic of China
2 shared publications- Dehui Che
Department of Plastic and Reconstructive, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 9029
Enhancing Exosome Production from Adipose-Derived Stem Cells via Arachidonic Acid Priming for Diabetic Wound Healing
Adipose-derived stem cell (ADSC)-derived exosomes are promising for regenerative therapy. However, their clinical translation is hindered by limited secretion yield and reduced functional potency. Here, we tested whether arachidonic acid (AA) priming increases exosome production while preserving exosomal identity, and whether AA-primed exosomes (AA-Exos) enhance diabetic wound repair. ADSCs were treated with AA, and exosome yield was quantified using particle counts and cumulative acetylcholinesterase (AChE) activity. Exosome morphology and canonical markers were assessed to confirm identity. Mechanistically, transcriptomic and functional analyses revealed that AA promoted multivesicular body and intraluminal vesicle formation through CHMP1B upregulation and facilitated exosome release through Rab27b, and knockdown of either gene impaired the corresponding process. Proteomic profiling further showed that AA-Exos were enriched in wound-repair-related cargo, particularly interleukin-8 (IL-8/CXCL8). In high-glucose-challenged endothelial cells, AA-Exos enhanced proliferation and migration and reduced apoptosis by activating FAK/AKT/ERK signaling, whereas IL-8 neutralization attenuated these effects. In a diabetic mouse model, AA-Exos accelerated wound closure and improved tissue perfusion, angiogenesis, and collagen deposition. Taken together, AA priming enhances exosome production while improving their therapeutic function, suggesting a practical strategy to strengthen the translational potential of ADSC-derived exosomes for diabetic wound regeneration.
- 12 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 9029
Open AccessEnhancing Exosome Production from Adipose-Derived Stem Cells via Arachidonic Acid Priming for Diabetic Wound Healing
Adipose-derived stem cell (ADSC)-derived exosomes are promising for regenerative therapy. However, their clinical translation is hindered by limited secretion yield and reduced functional potency. Here, we tested whether arachidonic acid (AA) priming increases exosome production while preserving exosomal identity, and whether AA-primed exosomes (AA-Exos) enhance diabetic wound repair. ADSCs were treated with AA, and exosome yield was quantified using particle counts and cumulative acetylcholinesterase (AChE) activity. Exosome morphology and canonical markers were assessed to confirm identity. Mechanistically, transcriptomic and functional analyses revealed that AA promoted multivesicular body and intraluminal vesicle formation through CHMP1B upregulation and facilitated exosome release through Rab27b, and knockdown of either gene impaired the corresponding process. Proteomic profiling further showed that AA-Exos were enriched in wound-repair-related cargo, particularly interleukin-8 (IL-8/CXCL8). In high-glucose-challenged endothelial cells, AA-Exos enhanced proliferation and migration and reduced apoptosis by activating FAK/AKT/ERK signaling, whereas IL-8 neutralization attenuated these effects. In a diabetic mouse model, AA-Exos accelerated wound closure and improved tissue perfusion, angiogenesis, and collagen deposition. Taken together, AA priming enhances exosome production while improving their therapeutic function, suggesting a practical strategy to strengthen the translational potential of ADSC-derived exosomes for diabetic wound regeneration.
- 30 July 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (7) , 3329-3346
DMBT1 in Adipose-Derived Stem Cell-Derived Exosomes Participates in Alleviating Ferroptosis to Promote Diabetic Wound Healing
Diabetic wounds represent one of the most severe complications of diabetes, and their clinical management remains challenging. This study investigated the therapeutic potential of adipose-derived stem cell-derived exosomes (ADSCs-Exo) for diabetic wounds. We isolated ADSCs and their exosomes, and by using Transwell and CCK-8 assays, we found that ADSCs-Exo were associated with proliferation and migration of keratinocytes and fibroblasts, and that they also enhanced the angiogenic activity of endothelial cells in vitro. In contrast, these promotive effects were significantly attenuated when exosomes derived from ADSCs with DMBT1 knockdown via siRNA (ADSCssiDMBT1-Exo) were applied. In a diabetic mouse model, ADSCs-Exo treatment significantly accelerated wound healing, whereas the pro-healing capacity of ADSCssiDMBT1-Exo was markedly reduced. To further explore the underlying mechanism, we performed RNA sequencing, which suggested that ADSCs-Exo might exert their therapeutic effects by alleviating ferroptosis and promoting cell proliferation. Subsequent experiments, including TEM, ROS assays, JC-1 staining, and tissue immunofluorescence, provided further support for these mechanistic findings. In summary, this study demonstrates that DMBT1 in ADSCs-Exo participates in alleviating ferroptosis in diabetic wound tissue, which may contribute to creating a favorable microenvironment for cell proliferation and promoting wound healing. This discovery provides a novel potential therapeutic target and strategy for the clinical treatment of diabetic wounds. Graphical Abstract ADSCs-Exo may be associated with ROS levels and inhibit ferroptosis in diabetic wound tissue with DMBT1 partially contributing to this effect, thereby creating a favorable microenvironment
- 30 July 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (7) , 3329-3346
DMBT1 in Adipose-Derived Stem Cell-Derived Exosomes Participates in Alleviating Ferroptosis to Promote Diabetic Wound Healing
Diabetic wounds represent one of the most severe complications of diabetes, and their clinical management remains challenging. This study investigated the therapeutic potential of adipose-derived stem cell-derived exosomes (ADSCs-Exo) for diabetic wounds. We isolated ADSCs and their exosomes, and by using Transwell and CCK-8 assays, we found that ADSCs-Exo were associated with proliferation and migration of keratinocytes and fibroblasts, and that they also enhanced the angiogenic activity of endothelial cells in vitro. In contrast, these promotive effects were significantly attenuated when exosomes derived from ADSCs with DMBT1 knockdown via siRNA (ADSCssiDMBT1-Exo) were applied. In a diabetic mouse model, ADSCs-Exo treatment significantly accelerated wound healing, whereas the pro-healing capacity of ADSCssiDMBT1-Exo was markedly reduced. To further explore the underlying mechanism, we performed RNA sequencing, which suggested that ADSCs-Exo might exert their therapeutic effects by alleviating ferroptosis and promoting cell proliferation. Subsequent experiments, including TEM, ROS assays, JC-1 staining, and tissue immunofluorescence, provided further support for these mechanistic findings. In summary, this study demonstrates that DMBT1 in ADSCs-Exo participates in alleviating ferroptosis in diabetic wound tissue, which may contribute to creating a favorable microenvironment for cell proliferation and promoting wound healing. This discovery provides a novel potential therapeutic target and strategy for the clinical treatment of diabetic wounds. Graphical Abstract ADSCs-Exo may be associated with ROS levels and inhibit ferroptosis in diabetic wound tissue with DMBT1 partially contributing to this effect, thereby creating a favorable microenvironment
- Open Access
Metabolic engineering of adipose‐derived stem cell exosomes via arachidonic acid potentiates diabetic wound repair by orchestrating angiogenesis: A multi‐omics guided strategy
Diabetic wounds are common and challenging complications of diabetes, characterized by delayed healing and an increased risk of infection. Exosomes derived from adipose‐derived stem cells (ADSCs) represent cell‐free therapeutic agents and are potential candidate drugs for treating diabetic wound healing. Our pre‐experimental and metabolomic analyses suggest that arachidonic acid (AA) metabolism can effectively promote wound healing in diabetic animal models. Exosomes from ADSCs pretreated with arachidonic acid (AA‐Exos) markedly improved the viability and proliferation of human umbilical vein endothelial cells under high glucose stress conditions, while also enhancing their biological functions, such as cell migration, angiogenesis, wound repair, and vascular endothelial growth factor (VEGF) expression. This study aimed to investigate the effect of AA‐Exos on the healing of diabetic wounds. Proteomic and transcriptomic analyses, along with pathway activation studies, revealed that AA‐Exos promoted angiogenesis by activating the PI3K/AKT/mTOR signaling pathway. In vivo experiments demonstrated that diabetic mice treated with AA‐Exos exhibited accelerated wound healing and increased vascularization. In addition, the compound stimulated collagen deposition and boosted VEGF and CD31 expression, indicating robust angiogenesis during diabetic wound healing. This study provides a novel perspective on exosome therapy for wound healing and effectively improves the therapeutic effects of exosomes.
Open AccessMetabolic engineering of adipose‐derived stem cell exosomes via arachidonic acid potentiates diabetic wound repair by orchestrating angiogenesis: A multi‐omics guided strategy
Diabetic wounds are common and challenging complications of diabetes, characterized by delayed healing and an increased risk of infection. Exosomes derived from adipose‐derived stem cells (ADSCs) represent cell‐free therapeutic agents and are potential candidate drugs for treating diabetic wound healing. Our pre‐experimental and metabolomic analyses suggest that arachidonic acid (AA) metabolism can effectively promote wound healing in diabetic animal models. Exosomes from ADSCs pretreated with arachidonic acid (AA‐Exos) markedly improved the viability and proliferation of human umbilical vein endothelial cells under high glucose stress conditions, while also enhancing their biological functions, such as cell migration, angiogenesis, wound repair, and vascular endothelial growth factor (VEGF) expression. This study aimed to investigate the effect of AA‐Exos on the healing of diabetic wounds. Proteomic and transcriptomic analyses, along with pathway activation studies, revealed that AA‐Exos promoted angiogenesis by activating the PI3K/AKT/mTOR signaling pathway. In vivo experiments demonstrated that diabetic mice treated with AA‐Exos exhibited accelerated wound healing and increased vascularization. In addition, the compound stimulated collagen deposition and boosted VEGF and CD31 expression, indicating robust angiogenesis during diabetic wound healing. This study provides a novel perspective on exosome therapy for wound healing and effectively improves the therapeutic effects of exosomes.
- 5 January 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (5) , 2195-2196
Reply to: Is Obesity Truly a Risk Factor for Keloid Development?
- 5 January 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (5) , 2195-2196
Reply to: Is Obesity Truly a Risk Factor for Keloid Development?
- 8 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178349
HY-021068 improves neuronal ferroptosis by activating Nrf2 signaling in APP/PS1 Mice and Aβ1-42-induced HT22 cells
- 8 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178349
HY-021068 improves neuronal ferroptosis by activating Nrf2 signaling in APP/PS1 Mice and Aβ1-42-induced HT22 cells
- 11 August 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 49 (19) , 5335-5340
Association of Keloid with Body Mass Index and Hypertension: A Retrospective Controlled Study
Little is known about the impact of chronic comorbidities on the onset and progression of keloid. The association between keloid and metabolic syndrome has not been investigated in observational controlled studies. To evaluate the association of keloid with obesity and hypertension using a population-based study. Information was collected on 151 patients with keloids, anywhere on the body, who visited the Plastic Surgery Department of the Second Affiliated Hospital of Anhui Medical University, and 164 control participants. The patient and control groups had similar mean ages. The mean ages of the patients and controls were 34.74 ± 16.25 years, and 35.50 ± 12.45 years, respectively. In the univariate analysis and multivariate analyses, body mass index ≥ 25 kg/m2 (OR = 1.546; p = 0.077) and systolic hypertension (OR = 3.859; p = 0.024) were related to keloid. The two risk factors were independent. Keloid was associated with overweight and systolic hypertension. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
- 11 August 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 49 (19) , 5335-5340
Association of Keloid with Body Mass Index and Hypertension: A Retrospective Controlled Study
Little is known about the impact of chronic comorbidities on the onset and progression of keloid. The association between keloid and metabolic syndrome has not been investigated in observational controlled studies. To evaluate the association of keloid with obesity and hypertension using a population-based study. Information was collected on 151 patients with keloids, anywhere on the body, who visited the Plastic Surgery Department of the Second Affiliated Hospital of Anhui Medical University, and 164 control participants. The patient and control groups had similar mean ages. The mean ages of the patients and controls were 34.74 ± 16.25 years, and 35.50 ± 12.45 years, respectively. In the univariate analysis and multivariate analyses, body mass index ≥ 25 kg/m2 (OR = 1.546; p = 0.077) and systolic hypertension (OR = 3.859; p = 0.024) were related to keloid. The two risk factors were independent. Keloid was associated with overweight and systolic hypertension. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
- Open Access
- 23 February 2024
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 20 (4) , 1026-1039
Exosomes Derived from Adipose Stem Cells Enhance Angiogenesis in Diabetic Wound Via miR-146a-5p/JAZF1 Axis
Chronic trauma in diabetes is a leading cause of disability and mortality. Exosomes show promise in tissue regeneration. This study investigates the role of exosomes derived from adipose stem cells (ADSC-Exos) in angiogenesis. MiRNA-seq analysis revealed significant changes in 47 genes in human umbilical vein endothelial cells (HUVECs) treated with ADSC-Exos, with miR-146a-5p highly expressed. MiR-146a-5p mimics enhanced the pro-angiogenic effects of ADSC-Exos, while inhibitors had the opposite effect. JAZF1 was identified as a direct downstream target of miR-146a-5p through bioinformatics, qRT-PCR, and dual luciferase assay. Overexpress of JAZF1 resulted in decreased proliferation, migration, and angiogenic capacity of HUVECs, and reduced VEGFA expression. This study proposes that ADSC-Exos regulate angiogenesis partly via the miR-146a-5p/JAZF1 axis. Graphical Abstract
- 23 February 2024
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 20 (4) , 1026-1039
Open AccessExosomes Derived from Adipose Stem Cells Enhance Angiogenesis in Diabetic Wound Via miR-146a-5p/JAZF1 Axis
Chronic trauma in diabetes is a leading cause of disability and mortality. Exosomes show promise in tissue regeneration. This study investigates the role of exosomes derived from adipose stem cells (ADSC-Exos) in angiogenesis. MiRNA-seq analysis revealed significant changes in 47 genes in human umbilical vein endothelial cells (HUVECs) treated with ADSC-Exos, with miR-146a-5p highly expressed. MiR-146a-5p mimics enhanced the pro-angiogenic effects of ADSC-Exos, while inhibitors had the opposite effect. JAZF1 was identified as a direct downstream target of miR-146a-5p through bioinformatics, qRT-PCR, and dual luciferase assay. Overexpress of JAZF1 resulted in decreased proliferation, migration, and angiogenic capacity of HUVECs, and reduced VEGFA expression. This study proposes that ADSC-Exos regulate angiogenesis partly via the miR-146a-5p/JAZF1 axis. Graphical Abstract
- 8 February 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (1) , 181-189
Predictors of amputation in patients with diabetic foot ulcers: a multi-centre retrospective cohort study
Purpose Investigating risk factors for amputation in patients with diabetic foot ulcer (DFU) and developing a nomogram prediction model. Methods We gathered case data of DFU patients from five medical institutions in Anhui Province, China. Following eligibility criteria, a retrospective case-control study was performed on data from 526 patients. Results Among the 526 patients (mean age: 63.32 ± 12.14), 179 were female, and 347 were male; 264 underwent amputation. Univariate analysis identified several predictors for amputation, including Blood type-B, Ambulation, history of amputation (Hx. Of amputation), Bacterial culture-positive, Wagner grade, peripheral arterial disease (PAD), and laboratory parameters (HbA1c, Hb, CRP, ALB, FIB, PLT, Protein). In the multivariate regression, six variables emerged as independent predictors: Blood type-B (OR = 2.332, 95%CI [1.488–3.657], p < 0.001), Hx. Of amputation (2.298 [1.348–3.917], p = 0.002), Bacterial culture-positive (2.490 [1.618–3.830], p p = 0.033), Wagner 4–5 (4.272 [2.444–7.468], p p = 0.036). We developed a nomogram prediction model utilizing the aforementioned independent risk factors. The model demonstrated a favorable predictive ability for amputation risk, as evidenced by its area under the receiver operating characteristics (ROC) curve of 0.756 and the well-fitted corrected nomogram calibration curve. Conclusion Our findings underscore Blood type-B, Hx. Of amputation, Bacterial culture-positive, Wagner 3–5, and PAD as independent risk factors for amputation in DFU patients. The resultant nomogram exhibits substantial accuracy in predicting amputation occurrence. Timely identification of these risk factors can reduce DFU-related amputation rates.
- 8 February 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (1) , 181-189
Predictors of amputation in patients with diabetic foot ulcers: a multi-centre retrospective cohort study
Purpose Investigating risk factors for amputation in patients with diabetic foot ulcer (DFU) and developing a nomogram prediction model. Methods We gathered case data of DFU patients from five medical institutions in Anhui Province, China. Following eligibility criteria, a retrospective case-control study was performed on data from 526 patients. Results Among the 526 patients (mean age: 63.32 ± 12.14), 179 were female, and 347 were male; 264 underwent amputation. Univariate analysis identified several predictors for amputation, including Blood type-B, Ambulation, history of amputation (Hx. Of amputation), Bacterial culture-positive, Wagner grade, peripheral arterial disease (PAD), and laboratory parameters (HbA1c, Hb, CRP, ALB, FIB, PLT, Protein). In the multivariate regression, six variables emerged as independent predictors: Blood type-B (OR = 2.332, 95%CI [1.488–3.657], p < 0.001), Hx. Of amputation (2.298 [1.348–3.917], p = 0.002), Bacterial culture-positive (2.490 [1.618–3.830], p p = 0.033), Wagner 4–5 (4.272 [2.444–7.468], p p = 0.036). We developed a nomogram prediction model utilizing the aforementioned independent risk factors. The model demonstrated a favorable predictive ability for amputation risk, as evidenced by its area under the receiver operating characteristics (ROC) curve of 0.756 and the well-fitted corrected nomogram calibration curve. Conclusion Our findings underscore Blood type-B, Hx. Of amputation, Bacterial culture-positive, Wagner 3–5, and PAD as independent risk factors for amputation in DFU patients. The resultant nomogram exhibits substantial accuracy in predicting amputation occurrence. Timely identification of these risk factors can reduce DFU-related amputation rates.
- Open Access
- 30 November 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (2) , 973-981
Application of free serratus anterior muscle-fascial composite tissue flap and facial lipofilling in repairing progressive hemifacial atrophy
- 30 November 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (2) , 973-981
Open AccessApplication of free serratus anterior muscle-fascial composite tissue flap and facial lipofilling in repairing progressive hemifacial atrophy